Braveheart Bio
San Francisco
About Braveheart Bio
Braveheart Bio is a biotechnology startup in late clinical development, working on innovative treatments for hypertrophic cardiomyopathy and related disorders. Braveheart's small molecule therapy candidate, BHB-1893, is a selective cardiac myosin inhibitor designed to improve heart function in HCM patients. Overcontraction in HCM can result in thicker heart muscle and a decline in the heart's ability to fill and pump blood. HCM is among the most frequent uncommon diseases, affecting one in every 500 people in the United States.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $185.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Nov 2025)
- Website: braveheart.bio
- Phone: [email protected]
Industries & Categories
Biotechnology, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/braveheart-bio-44617 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.